Pulmatrix Inc (PULM): GSK Advair lost generic protection in 20...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	0
Posts	110
Boards Moderated	0
Alias Born	03/08/2017

StocksInvestor

Re: iambillytalent post# 1311

Thursday, 03/30/2017 7:25:48 AM

Thursday, March 30, 2017 7:25:48 AM

GSK Advair lost generic protection in 2015 that yr they made $8B in rev COPD and Asthama

Too big for Mylan to ignore. GSK could go into a bidding war and try to take over PULM from Mylan to completely take them out of the $30B COPD market. If I can remove my biggest competitor spending around $250M why would not do it

This could very interesting very soon

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent PULM News

Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:06:11 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:00:24 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 02:20:24 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:05:40 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 01:20:24 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 01:05:29 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 08:05:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 01:05:21 PM